Reading STXS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track STXS free→Reading STXS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track STXS free→AMEXHealth CareMedical Instruments & SuppliesSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been steady. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, STXS trades below typical levels. Peer multiples imply a price about 32% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern occurs because it trades below peer multiples, but recent financials are weak. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $1.83. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $1.83 STXS trades at 6× p/s — 2.3× the 3× p/s peer median. The market is re-rating it beyond its own range; our $2.73 fair value is low-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 33% below a flat-multiple fair value, below our forecast of about 10%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.71x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.05 → $-0.05 (+11.0% / 30d). 1 raised, 0 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$219.
How much price usually moves either way.
On a bad day, this stock has moved -$567.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,154.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If management score goes up, it may show more confidence and better execution.
Confirms:Management score increases by more than 5 points in the next quarter.
Disproves:Management score declines or stays the same in the next quarter.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for STXS yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition On May 12, 2026, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2026 first quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein. Forward-Looking Statements and Additional Information Statements are made herein or incorporated herein that are “forward-looking s…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
STXS Stereotaxis, Inc. | Below typical Show detailsSector percentile: 4 of 100 | inexpensive | elevated |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 77 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 94 of 100 | fair | elevated |
4 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Stereotaxis aims for double-digit revenue growth for the full year 2026, with annual revenue expected to surpass $40 million.
Stated in 2 of last 2 quarters. Revenue in 2026-Q1 was $6.29 million, down from $8.64 million in 2025-Q4, indicating a decline rather than growth. Despite the stated goal of double-digit growth, the trajectory shows limited progress so far.
“Stereotaxis anticipates double digit revenue growth for the full year 2026...”
“this supports annual revenue growth for the current year of over 20%”
Stereotaxis expects revenue in both the third and fourth quarters of 2026 to exceed $10 million.
Newly stated in 2026-Q1. Current revenue in 2026-Q1 is $6.29 million, which is below the $10 million target for Q3 and Q4. The company needs significant growth to meet this guidance, indicating a challenging trajectory ahead.
“Revenue in both the third and fourth quarters expected to exceed $10 million.”
Stereotaxis completed the acquisition of Robocath, acquiring 100% of its share capital and voting power.
Newly stated in 2026-Q1. The acquisition of Robocath was completed, marking a strategic move in M&A activity. This could potentially enhance Stereotaxis' market position, but the financial impact remains to be seen in future quarters.
“Stereotaxis entered into a Share Sale Agreement to acquire 100% of Robocath.”
Why it matters: If valuation changes from 'inexpensive', it may show how the market thinks.
Confirms one read:Valuation label changes to 'expensive' in the next earnings report.
Confirms the other:The valuation label will stay 'inexpensive' in the next earnings report.
Why it matters: If healthcare revenue growth speeds up, it could help Stereotaxis's market position.
Confirms:Healthcare revenue growth speeds up to more than 10% year over year.
Disproves:Healthcare revenue growth slows down below 10% year over year.
Entry into a Material Definitive Agreement On April 14, 2026, Stereotaxis, Inc. (“Stereotaxis” or the “Company”) entered into a Share Sale Agreement with Robocath, a French société par actions simplifiée , (“Robocath”), the shareholders of Robocath party thereto (the “Sellers”) and an individual serving as manager (the “Manager”) to acquire (the “Acquisition”) shares and other securities collectively representing 100% of the share capital and voting power of Robocath (on a fully-diluted basis…
Unregistered Sales of Equity Securities The information set forth above in the first five paragraphs of
Results of Operations and Financial Condition On March 9, 2026, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2025 fourth quarter and full year. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein. Forward-Looking Statements and Additional Information Statements are made herein or incorporated herein that are “f…
Results of Operations and Financial Condition On November 11, 2025, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2025 third quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein. Forward-Looking Statements and Additional Information Statements are made herein or incorporated herein that are “forward-look…